Moolec Science MLECW
NASDAQ MLECW
$0.02 +0.00 (+2.56%)
As of: Aug 19, 2026 · 2:06 PM EDT

Moolec Science (MLECW) Non-Current Deffered Revenue (2023 - 2025)

Moolec Science (MLECW) posted Non-Current Deffered Revenue of $1260.0 for Q2 2025, down 99.93% sequentially from $1.9 million in Q2 2024, and down 99.93% YoY from $1.9 million in Q2 2024.

Moolec Science (MLECW) Non-Current Deffered Revenue (2023 - 2025) Analysis & Trends

Moolec Science has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $1260.0 in Q2 2025.

  • Quarterly Non-Current Deffered Revenue fell 99.93% year-over-year to $1260.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1260.0 (down 99.93% YoY) and the FY2025 annual result came in at $1260.0, down 99.93% from the prior year.
  • Non-Current Deffered Revenue slipped to $1260.0 in Q2 2025 per MLECW's latest filing, from $1.9 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $24.9 million in Q2 2023 and troughed at $1260.0 in Q2 2025.
  • A 3-year average of $8.9 million and a median of $1.9 million in 2024 frame the typical range for Non-Current Deffered Revenue.
  • The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue sank 92.27% in 2024, then slumped 99.93% in 2025.
  • Over 3 years, Non-Current Deffered Revenue stood at $24.9 million in 2023, then tumbled by 92.27% to $1.9 million in 2024, then plunged by 99.93% to $1260.0 in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1260.0, $1.9 million, and $24.9 million for Q2 2025, Q2 2024, and Q2 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 147.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Moolec Science 8,617.72 -1.19 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 1,260.00
Jun 30, 2024 1.93 Mn
Jun 30, 2023 24.89 Mn